Our study demonstrated that inhibiting γ-secretase can improve the treatment of PNI in CRC in preclinical models, and this effect is mediated at least in part by inhibition of CD51-ICD production, despite the known crosstalk between γ-secretase inhibition and the NOTCH pathway [24]. This evidence concerns the gene ITGAV and colorectal carcinoma.